Chronic Obstructive Pulmonary Disease (COPD) Market (2024 - 2034)

Chronic Obstructive Pulmonary Disease (COPD) Market Size and Share Forecast Outlook (2023 to 2033)

The global Chronic Obstructive Pulmonary Disease (COPD) market size is expected to be valued at USD 21.58 billion in 2023. With the increasing alcohol consumption among people, the overall demand for Chronic Obstructive Pulmonary Disease (COPD) is projected to grow at a CAGR of 4.4% between 2023 and 2033, totaling around USD 33.19 billion by 2033.

Data Points	Key Statistics
Chronic Obstructive Pulmonary Disease (COPD) Market Value 2023	USD 21.58 Billion
Chronic Obstructive Pulmonary Disease (COPD) Market Projected Value (2033)	USD 33.19 Billion
Chronic Obstructive Pulmonary Disease (COPD) Market CAGR (2023 to 2033)	4.4%

According to the analysis of Future Market Insights, the Chronic Obstructive Pulmonary Disease (COPD) market is expected to fuel over the analysis period, attributed to an increase in patient population, due to a substantial rise in incidence as well as the prevalence of asthma.

As per a 2021 factsheet from the World Health Organization (WHO), asthma is a major non-communicable disease (NCD), affecting both children as well as adults. Globally, it affected an estimated 262 million people in 2019 and caused 461,000 deaths.

Enormous investments in the study of asthma drugs, accompanied by strategic collaborations such as mergers and acquisitions are the business strategies followed by the major companies in the market. Hence, the aforementioned factors are anticipated to boost the growth of the COPD market during the forecast period.

Comparison of 2018 to 2022 Demand vs 2023 to 2033 Outlook for Chronic Obstructive Pulmonary Disease (COPD)

The global demand for Chronic Obstructive Pulmonary Disease (COPD) is projected to increase at a CAGR of 4.4% during the forecast period between 2023 and 2033, reaching a total of USD 33.19 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 2.4%.

According to Future Market Insights, a market research and competitive intelligence provider, the Chronic Obstructive Pulmonary Disease (COPD) market was valued at USD 20.67 Billion in 2022.

As per a March 2021 study by José Luis Izquierdo et al., published in the European Respiratory Journal, allergy-related factors such as eczema and rhinitis were less common in asthmatic patients with COVID-19. Though, there was a high prevalence of these comorbidities observed in patients with COVID-19, who required hospital admission.

The continual rise in the geriatric population worldwide is a major factor driving market growth. As the World Ageing 2020 report, in 2020, there were around 727 million people aged 65 years or more in the world.

In addition, the number of older persons is projected to double to 1.5 billion in 2050. Globally, the share of the population aged 65 years or over increased from 9.3% in 2020 to reach 16% by 2050. Thus, the growing geriatric population is likely to fuel the market growth during the analysis period, owing to the fact that asthma is a widely prevalent disease found in people over the age of 65.

Moreover, technological advancements are another major factor that is projected to create lucrative avenues for market growth. Also, limitations of traditional treatments, such as the late onset of action as well as low efficacy, are anticipated to encourage the development of novel targeted drugs, which in turn are propelling market growth.

Key Drivers Supporting Growth in the Chronic Obstructive Pulmonary Disease (COPD) Industry

Awareness Efforts by Individual Organizations to Fuel the Market Growth

As per a 2019 study published by the National Center for Biotechnology Information, globally, 212.3 million prevalent cases of chronic obstructive pulmonary disease (COPD) were reported, with COPD accounting for 3.3 million deaths and 74.4 million disability-adjusted life years.

In addition, as per the American Lung Association, in 2018, 9.0 million adults, or 3.6% of those aged 18 or older, had chronic bronchitis. In 2018, 16.4 million people, or 6.6% of adults, reported a diagnosis of any type of COPD (chronic bronchitis, emphysema, or COPD). Hence, the rise in the incidence of chronic obstructive pulmonary disease is anticipated to augment the market growth in the near future.

Additionally, in November 2021, as per the data published by the National Heart, Lung and Blood Institute, each November, the chronic obstructive pulmonary disease (COPD) community comes together to promote a better understanding of COPD, a progressive lung disease that affects millions across the US.

Further, rising awareness among the people, regarding chronic obstructive pulmonary disease (COPD) and its symptoms is important as early diagnosis, as well as treatment can improve quality of life.

Rise in Adoption of More Effective Combination Therapy to Accelerate the Market Growth

The combination therapies include LABA-ICS, triple therapy, LAMA-ICS, and other combination drugs. The adoption of combination therapy is surging, as it is more effective than the separate use of bronchodilators and corticosteroids.

Moreover, a rise in the number of patients successfully treated with combination therapy, who were not showing signs of recovery with bronchodilators or corticosteroid treatments is a major factor that is projected to accelerate the global chronic obstructive pulmonary disease market in the forthcoming years. Also, combination therapy is considered to be more effective than monotherapy for improving symptoms as well as the quality of life.

Challenges Limiting Expansion of the Chronic Obstructive Pulmonary Disease (COPD) Market

The Side Effects of COPD Drugs to Restrain the Market Growth

The side effect of the drugs used in treating chronic obstructive pulmonary disease is one of the major factors hindering the growth of the COPD market during the analysis period. For instance, as per the data published by the National Center for Biotechnology Information, there are some serve side effects associated with the drugs that are used in the treatment of chronic obstructive pulmonary disease, namely oral infections, bruising, and hoarseness.

Moreover, these medications are useful for people with frequent exacerbations of Chronic Obstructive Pulmonary Disease. An instance of inhaled steroids includes Fluticasone (Flovent HFA). Also, respiratory infections are observed in people with COPD, who are more likely to catch flu, colds, and pneumonia.

Chronic Obstructive Pulmonary Disease can cause many complications like depression, heart problems, high blood pressure in lung arteries, and lung cancer in some cases.

Challenges of New Drug Development to Limit the Market Growth

Drug failures (termination) in clinical trials as well as the development of new drugs are challenging tasks that are anticipated to impede the growth of the COPD market in the near future. For instance, in May 2019, benralizumab, an asthma drug failed to decrease annual COPD exacerbation rates for patients with moderate to very severe COPD.

Additionally, the Phase III, randomized, placebo-controlled, double-blind, parallel-group clinical trials TERRANOVA and GALATHEA evaluated the efficacy and safety of benralizumab, for the prevention of exacerbations in patients with moderate to very severe COPD.

Analysis of Regional Trends Influencing COPD Diagnosis and Therapy Adoption

Will North America Continue Dominance in the Global Chronic Obstructive Pulmonary Disease (COPD) Market?

Well-Structured Healthcare Industry in the Region to Fuel the Market Growth

The Chronic Obstructive Pulmonary Disease (COPD) Market in North America is expected to accumulate the highest market share of 44% in 2023.

The regional market growth is attributed to the factors such as the availability of well-defined reimbursement policies from private and public health insurance firms, and the highly structured healthcare industry in the region.

Moreover, the presence of a large number of players in North America, coupled with an increase in research & development activities to provide advanced and efficient products, are other factors boosting the growth of the COPD market in the region.

As per the Lung Association, COPD is prevalent in men and women and is the sixth most common factor of hospitalization in women and fourth most in men in Canada. The market is also driven by factors including the rapid pace of industrialization, exponentially increasing air pollution, and the adoption of a sedentary lifestyle in the region.

Also, lack of awareness of COPD, and the increasing smoking population are other factors that are likely to escalate the regional market growth during the forecast period. The region is expected to hold the highest CAGR of 4.3% during the forecast period.

How Will the Growth of the Chronic Obstructive Pulmonary Disease (COPD) Market unfold in Asia Pacific?

Increase in Geriatric Population in the Region to Fuel the Market Growth

The Chronic Obstructive Pulmonary Disease (COPD) Market in Asia Pacific is expected to accumulate the second-highest market share of 43% in 2023.

Asia Pacific has a relatively untapped chronic obstructive pulmonary disease treatment market, compared to the developed regions such as North America and Europe.

Therefore, the region offers lucrative opportunities to COPD market players. Factors such as a surge in the geriatric population, high incidence of chronic obstructive pulmonary disease, and rise in patient population are expected to fuel the COPD market in the region.

Furthermore, the Asia Pacific COPD market is largely driven by the rising prevalence of respiratory distress conditions. For instance, as per the data published by the World Health Organization (WHO), due to COPD, more than 90% of deaths occur in low and middle-income countries.

Rapid urbanization that causes an increase in air pollution provides amplifies the predisposition to acquire respiratory diseases like COPD, thus creating significant avenues for the COPD drugs market in the region. Asia Pacific is expected to hold the highest CAGR of 4.2% during the forecast period.

Chronic Obstructive Pulmonary Disease (COPD) Industry Analysis by Top Investment Segments

By Drug Class, which Chronic Obstructive Pulmonary Disease (COPD) Category will remain prominent?

Combination Therapy Segment to beat Competition in Untiring Market

On the basis of drug class, the global Chronic Obstructive Pulmonary Disease (COPD) market is dominated by the Combination Therapy Segment, which accounts for a share of 45%. The segment is expected to hold a CAGR of 4.3% over the analysis period.

The segment is expected to dominate the global market over the analysis period, attributed to the increase in the efficacy of combination therapy in COPD treatment. In addition, an increase in the success rate of combination therapy in COPD treatment, and recent regulatory approvals are anticipated to propel the adoption of combination therapy.

By Type, which Chronic Obstructive Pulmonary Disease (COPD) Category dominates?

Chronic Bronchitis Segment to Drive the Chronic Obstructive Pulmonary Disease (COPD) Market

Based on the Type, the chronic bronchitis segment is expected to witness a significant growth of 43% in 2022, and the trend is expected to continue during the forecast period, expanding at a rapid rate of 4.2% CAGR over the analysis period.

The segment’s growth is attributed to the factors such as the fact that chronic bronchitis is a group of lung diseases that causes airflow blockage and breathing issues. It is widespread among smokers and rising at a rapid pace. Hence, an upsurge in breathing issues among smokers, coupled with a rise in airflow blockage is a major factor fueling the segment’s growth during the forecast period.

By Distribution Channel, which Chronic Obstructive Pulmonary Disease (COPD) Category dominates?

Retail Pharmacies Segment to Drive the Chronic Obstructive Pulmonary Disease (COPD) Market

Based on the Distribution Channel, the retail pharmacies segment is expected to witness a significant growth of 42% in 2022, and the trend is expected to continue during the forecast period, expanding at a rapid rate of 4.2% CAGR over the analysis period.

The segment is expected to grow at a rapid pace in the forthcoming years, owing to the factors such as an increase in the number of retail pharmacies in developing countries, as well as an increase in the number of COPD therapeutics dispensed through retail pharmacies.

Start‑up Ecosystem and Innovation Driving Future Growth in the Chronic Obstructive Pulmonary Disease (COPD) Market

Chronic Obstructive Pulmonary Disease (COPD) Market startup players are adopting various marketing strategies such as new product launches, geographical expansion, mergers and acquisitions, partnerships, and collaboration to identify the interest of potential patients and create a larger customer base. For instance,

• Founded in 2015, Chance Pharmaceuticals is a developer of transformative inhalation therapies for pulmonology disorders. The company's lead candidate CXF11 is a tiotropium bromide inhalation drug for the prevention of bronchospasm in patients with chronic obstructive pulmonary disease. In addition, developing an inhaler to disperse powder and deliver particles to the lung.
• Synspira, a startup established in 2017, is developing a novel class of inhalable glycopolymer-based therapeutics for pulmonary diseases including cystic fibrosis, chronic obstructive pulmonary disease (COPD), and pneumonia. The company has an exclusive license from Synedgen to the Glycomics Technology Platform for the development of inhaled glycopolymer-based therapeutics in pulmonary indications. Its drug pipeline includes SNSP 113 to improve the lung function of cystic fibrosis (preclinical) patients, SNSP 115 to treat pneumonia (preclinical), and SNSP 146 to treat COPD (preclinical). The company is using proprietary modified polysaccharide molecules to disrupt bacterial biofilms and to help expectorate mucus, exposing otherwise protected bacteria to antibiotics.
• Started in 2016, Suzhou Xinmaide is a developer of drug-delivery devices for the treatment of respiratory diseases. The company's products include single-dose capsule DPI devices, multi-dose blister DPI devices, soft mist inhalation devices, and multi-power nasal spray devices for the delivery of drugs for diseases such as asthma, chronic obstructive pulmonary disease (COPD), nose and brain.

Leading Companies Operating in the Chronic Obstructive Pulmonary Disease (COPD) Market

Prominent players in the Chronic Obstructive Pulmonary Disease (COPD) market are Almirall, AstraZeneca, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Kyowa Hakko Kirin, Mylan N.V., Novartis AG, Orion Corporation, Sanofi, Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.), Teva Pharmaceutical Industries Ltd., Theravance Biopharma, and Verona Pharmaceuticals, among others.

Recent Developments:

• In January 2022, the first patient was enrolled in a phase 4 study comparing Yupelri (revefenacin) to Spiriva (tiotropium) in improving lung health in adults with severe chronic obstructive pulmonary disease (COPD). The safety of these two approved once-daily COPD maintenance treatments would be assessed as well. Yupelri is a bronchodilator, a type of medication that relaxes and widens the lung airways, making breathing easier. It was developed by Theravance Biopharma and Mylan (now part of Viatris). It is available as an inhalable solution via a nebulizer, a small machine that turns liquid into a fine mist.
• In November 2021, AstraZeneca announced that it had sold rights to sell Tudorza, also known as Eklira abroad, and Duaklir to the Switzerland-based pharmaceutical company Covis Pharma Group for USD 270 Million. These products are indicated for the treatment of chronic obstructive pulmonary disease (COPD).
• In October 2021, Mylan Pharmaceuticals received FDA approval for its investigational new drug application (ANDA) for Breyna (budesonide and formoterol fumarate dihydrate inhalation aerosol), the first approved generic version of AstraZeneca's Symbicort. It is anticipated to be available in dosage strengths of 160 mcg/4.5 mcg and 80 mcg/4.5 mcg for patients with asthma or chronic obstructive pulmonary disease (COPD).

Key Highlights from the Chronic Obstructive Pulmonary Disease (COPD) Industry Report

Report Attribute	Details
Growth Rate	CAGR of 4.4% from 2023 to 2033
Market Value in 2023	USD 21.58 Billion
Market Value in 2033	USD 33.19 Billion
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Drug Class, Type, Distribution Channel, Region
Regions Covered	North America; Europe; Asia Pacific; Latin America; Middle East & Africa (MEA)
Key Countries Profiled	The USA, Canada, Brazil, Mexico, Germany, The UK, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC, South Africa, Israel
Key Companies Profiled	Almirall; AstraZeneca; Boehringer Ingelheim International GmbH; CHIESI Farmaceutici S.p.A.; F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc; Kyowa Hakko Kirin; Mylan N.V.; Novartis AG; Orion Corporation; Sanofi; Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.); Teva Pharmaceutical Industries Ltd.; Theravance Biopharma; Verona Pharmaceuticals

Top Segments Studied in the Chronic Obstructive Pulmonary Disease (COPD) Industry Analysis

By Drug Class:

• Combination Therapy
• Bronchodilators
• Corticosteroids
• Phosphodiesterase Type 4 Inhibitor
• Mucokinetics
• Others

By Type:

• Chronic Bronchitis
• Emphysema

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa